Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  HOOKIPA Pharma Inc.    HOOK

HOOKIPA PHARMA INC.

(HOOK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2020 09/23/2020 09/24/2020 09/25/2020 09/28/2020 Date
9.53(c) 9.55(c) 9.69(c) 9.95(c) 9.94(c) Last
61 008 45 698 39 563 52 734 41 124 Volume
-3.93% +0.21% +1.47% +2.68% -0.10% Change
More quotes
Financials (USD)
Sales 2020 19,4 M - -
Net income 2020 -44,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,88x
Yield 2020 -
Sales 2021 9,65 M - -
Net income 2021 -62,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,88x
Yield 2021 -
Capitalization 255 M 255 M -
Capi. / Sales 2020 13,2x
Capi. / Sales 2021 26,4x
Nbr of Employees 95
Free-Float 72,5%
More Financials
Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation... 
More about the company
Notations Surperformance© of HOOKIPA Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about HOOKIPA PHARMA INC.
09/17HOOKIPA PHARMA : to Present at SVB Leerink's CybeRx Series Vaccine Forum
AQ
09/17HOOKIPA PHARMA : LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High I..
AQ
09/16HOOKIPA PHARMA : LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High I..
AQ
09/16HOOKIPA Pharma's LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates Hig..
GL
09/16HOOKIPA PHARMA : to Present at SVB Leerink's CybeRx Series Vaccine Forum
AQ
09/16HOOKIPA Pharma to Present at SVB Leerink's CybeRx Series Vaccine Forum
GL
09/09HOOKIPA PHARMA : to Present at Upcoming Conferences in September
AQ
09/09HOOKIPA Pharma to Present at Upcoming Conferences in September
GL
08/13HOOKIPA PHARMA : Management's Discussion and Analysis of Financial Condition and..
AQ
08/13HOOKIPA PHARMA INC. : Results of Operations and Financial Condition, Financial S..
AQ
08/13HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a C..
GL
08/04HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, ..
GL
08/03HOOKIPA Announces Issuance of US and European Patents
GL
06/22HOOKIPA PHARMA INC. : Regulation FD Disclosure, Other Events, Financial Statemen..
AQ
06/22HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results ..
GL
More news
News in other languages on HOOKIPA PHARMA INC.

- No features available -

More news
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,75 $
Last Close Price 9,94 $
Spread / Highest target 101%
Spread / Average Target 78,6%
Spread / Lowest Target 50,9%
EPS Revisions
Managers
NameTitle
Jörn Aldag Chief Executive Officer & Director
Jan G. J. van de Winkel Chairman
Reinhard Kandera Chief Financial Officer & Director
Igor Matushansky Chief Medical Officer & Global Head-Research
Roman Necina Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
HOOKIPA PHARMA INC.-18.72%255
JOHNSON & JOHNSON0.85%387 315
ROCHE HOLDING AG4.46%302 660
MERCK & CO., INC.-9.00%209 320
PFIZER, INC.-7.99%202 215
NOVARTIS AG-12.09%192 245